To estimate the cost-effectiveness of nilotinib compared to imatinib as first-line (FL) treatment for newly diagnosed patients with Phϩ CML-CP. METHODS: A literature-based Markov model was developed to estimate the costs of Phϩ CML-CP patients initiating therapy with nilotinib or imatinib. Direct expenses associated with Phϩ CML-CP and resulting follow-up costs were calculated using general tariff agreement of Russian obligatory insurance system and official national statistics. For reference, accepted exchange rate was 1 EUR ϭ 40 RUB. RESULTS: Compared to FL imatinib, FL nilotinib results in increases in discounted FL drug therapy costs: 17 283 587 RUB (432 090 EUR) in imatinib group and 19 826 435 RUB (495 661 EUR) in nilotinib group per patient for life expectancy (17.3 and 18.82 respectively). The discounted incremental cost/LYG and cost/QALY are estimated at 1 672 926 RUB (41 823 EUR) and 1 829 387 RUB (45 735 EUR), respectively. CONCLUSIONS: The results of cost-effectiveness illustrate that FL nilotinib is acceptable in Russian patients with Phϩ CML-CP who are initiating tyrosine kinase inhibitors therapy and has to be recommended as first-line (FL) treatment for newly diagnosed patients with Phϩ CML-CP.
PCN94 FEASIBILITY OF EFFICIENCY FRONTIER ANALYSIS (EFA) IN METASTATIC BREAST CANCER (MBC) TREATMENTS: A UK PERSPECTIVE
Burudpakdee C 1 , Bertwistle D 2 1 IMS Health, Alexandria, VA, USA, 2 IMS Health, London, UK OBJECTIVES: EFA may be useful for assessing the efficiency of newer interventions. This study evaluated whether EFA could be useful in identifying the efficiency of mBC therapies adopted by the NHS, and to identify the efficiency frontier for newer technologies. METHODS: A literature search identified mBC treatments that underwent HTA in the UK. Reports were reviewed to identify treatment efficacy and HTA recommendations. Costs were determined for a course of treatment. The incremental costs per patient were plotted on the horizontal axis and incremental median overall survival (⌬OS) of treatment was plotted on the vertical axis to construct the EFA line. Treatments below this line are considered inefficient. Treatments above this line have better OS and may redefine the efficiency frontier. Treatments in the upper right quadrant beyond the frontier line are in an area where ceiling price has not been defined. Treatments in the lower right quadrant beyond the frontier line are inefficient due to higher cost for lower OS. RESULTS: Ten reports that evaluated efficacy in terms of median OS were included in the EFA. The therapies are paclitaxel albumin, gemcitabine, trastuzumab, bevacizumab, lapatinib, eribulin and fulvestrant. On the frontier line are paclitaxel albumin (⌬OS of 2.3 months at £2020), gemcitabine (⌬OS of 2.8 months at £6020), and trastuzumab (⌬OS of 4 months at £16939); all received positive recommendations. Lapatinib (⌬OS of 1.9 months at £10180), bevacizumab (⌬OS of 1.7 months at £36560), eribulin (⌬OS of 2.5 months at £4834) and fulvestrant (⌬OS of 2.3 months at £2481) are all below the frontier line and received negative recommendations. CONCLUSIONS: EFA may be a useful method for assessing the efficiency of new mBC treatment options for clinical use. Further studies are needed to better understand value in terms of efficiency of treatments in other tumor types and disease areas. OBJECTIVES: A capecitabine (Xeloda®) chemotherapy combination regimen has been shown to be non-inferior in terms of comparative effectiveness and safety over 5-Fluorouracil (5-FU) combination chemotherapy in advanced oesophagogastric cancer (eGC). The objective of this economic evaluation, which was based on two randomised phase III, non-inferiority clinical trials, REAL-2 and ML17032, was to compare the direct medical costs to the Australian health care system of capecitabine (X) versus 5-FU (F), when used in combination with epirubicin plus cisplatin (EC) as triplet therapy (ECX versus ECF), and when used in combination with cisplatin as doublet therapy (CX vs CF). METHODS: Direct medical costs were estimated for five treatment settings from both a public and private hospital perspective. Costs included in the economic evaluation were costs of drug acquisition (calculated using trial-based mean cumulative doses), drug preparation (5-FU), drug administration and drug wastage. The cost of drug acquisition was calculated based on dosage data and the mean number of treatment cycles from the REAL-2 and ML17032 trials. There were no costs associated with preparing capecitabine. An Oncology Grouping and Costing Study was performed to determine the relevant administration costs associated with a central venous access device, its placement, maintenance and removal (as required for 5-FU administration) and the continuous infusion of 5-FU via a Continuous Ambulatory Delivery Device pump or infuser. RESULTS: This economic evaluation has shown that treating advanced eGC patients with capecitabine in a triplet and a doublet chemotherapy combination results in average cost savings of $5,291 and $2,142 respectively, when compared with 5-FU. A multi-way sensitivity analysis demonstrated that the use of capecitabine remained cost-saving from an Australian government health budget perspective ($1765 and $340, respectively) . CONCLUSIONS: The use of capecitabine, compared with 5-FU, for the treatment of advanced eGC is cost-saving from an Australian government health budget perspective.
PCN95 PHARMACOECONOMIC ANALYSIS OF DIRECT MEDICAL COSTS ASSOCIATED WITH THE TREATMENT OF ADVANCED ESOPHAGO-GASTRIC CANCER THERAPY WITH XELODA OR 5-FLUOROURACIL (5-FU) REGIMENS: IMPLICATIONS FOR HEALTH CARE UTILISATION IN AUSTRALIA

PCN96 COST MINIMIZATION ANALYSIS OF XELODA® VERSUS 5-FLUOROURACIL-BASED TREATMENT FOR GASTRIC CANCER PATIENTS IN HONG KONG
Zhou KR 1 , Cheng A 2 , Kwok TY 1 , Yao R 2 , Yip E 2 , Lee VW 1 1 The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, 2 Princess Margaret Hospital, Kowloon, Kowloon, Hong Kong OBJECTIVES: EOX (epirubicin, oxaliplatin, Xeloda ® ) and FOLFOX4 (5-fluorouracil (5-FU), leucovorin, oxaliplatin) are the common chemotherapy regimens used in the treatment of advanced gastric cancer (aGC) in Hong Kong. Previous clinical studies have shown the Xeloda ® -based regimen, EOX, to be non-inferior to the 5-FU-based counterpart, FOLFOX4, in terms of efficacy. This study aims to compare the costs of these therapies from both the health care and societal perspectives. METHODS: Thirty-seven patients were identified from the electronic records at a public tertiary hospital, with 26 and 11 received EOX and FOLFOX4 regimens respectively. Health care cost refers to direct medical costs including drugs, clinic follow-up, hospitalization, diagnostic laboratories and radiographs. Societal cost refers to indirect costs such as patient time and travel costs. Cost items were further classified as ЉexpectedЉ or ЉunexpectedЉ. All cost data was expressed in Hong Kong dollars (app. 10HKD ϭ 1Euro). RESULTS: Patients in the EOX and FOL-FOX4 arm received an average of 5.3 and 7.5 cycles of treatment respectively. The Xeloda ® -based regimen group had a higher expected medication cost when compared to the 5-FU-based treatment group ($5145.3 vs. $2515.3, pϽ0.001) but lower expected hospitalization costs ($600 vs. $9900, pϽ0.001) and associated time costs ($812.6 vs. $1197.3, pϭ0.001) due to fewer hospital bed-days required for delivery. The total health care cost and total societal cost per patient was reduced by 59.3% ($58541.2 vs. $143914.1, pϽ0.001) and 42.6% ($8127.5 vs. $14151.3, pϽ0.001) respectively in the Xeloda ® -based regimen group. Sensitivity analyses based on full cycle regimen costs and net Xeloda ® or 5-FU/leucovorin costs still showed EOX to be less costly than FOLFOX4. CONCLUSIONS: The Xeloda ® -based regimen, EOX, was found to generate significant cost saving in both health care and societal perspectives. Provided the similar efficacy between EOX and FOLFOX4 in aGC treatment, the Xeloda ® -based therapy is more cost-effective and should be advocated when appropriate.
